Orchestra BioMed Holdings, Inc. (OBIO)Healthcare | Biotechnology | New Hope, United States | NasdaqGM
5.72 USD
-0.19
(-3.215%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 5.72 |
Hot Take ↕ | Oct. 10, 2026, 3:17 a.m. EDT
The investment case here is structurally broken. While the balance sheet appears liquid with a high current ratio, the business is hemorrhaging cash with negative operating and free cash flows, and revenue has collapsed by nearly 90% year-over-year. The market has correctly priced this as a value trap; the stock has lost over 70% of its value over the last five years, with the last three years showing consecutive declines. Despite a 'strong buy' analyst recommendation based on potential future readouts, the current reality is a deteriorating asset with no earnings power. The options market confirms this pessimism, with massive put buying indicating a fear of further collapse. There is no dividend to cushion the blow, and the lack of insider selling is a minor silver lining in an otherwise bleak landscape. Avoid. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.310144 |
| AutoARIMA | 0.314252 |
| AutoETS | 0.314253 |
| AutoTheta | 0.319155 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 12.68 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.184 |
| Excess Kurtosis | -1.23 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 240.517 |
| Revenue per Share | 0.537 |
| Market Cap | 343,800,864 |
| Forward P/E | -3.79 |
| Beta | 0.52 |
| Profit Margins | -184.60% |
| Previous Name | Health Sciences Acquisitions Corporation 2 |
| Website | https://www.orchestrabiomed.com |
As of Oct. 10, 2026, 3:17 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside participation. Put open interest significantly exceeds call open interest across all expirations, with heavy concentration in out-of-the-money strikes ($5.00 and $2.50). This 'bear put spread' structure suggests traders expect further price erosion, likely targeting the $2.85 fifty-two-week low, while call activity remains negligible despite the stock trading near its highs relative to recent lows.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.6601124 |
| Address1 | 150 Union Square Drive |
| All Time High | 23.39 |
| All Time Low | 2.2 |
| Ask | 5.35 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 276,700 |
| Average Daily Volume3 Month | 301,204 |
| Average Volume | 301,204 |
| Average Volume10Days | 276,700 |
| Beta | 0.516 |
| Bid | 3.0 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 0.321 |
| City | New Hope |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.72 |
| Current Ratio | 8.258 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 5.87 |
| Day Low | 5.71 |
| Debt To Equity | 240.517 |
| Display Name | Orchestra BioMed |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -57,642,000 |
| Ebitda Margins | -1.8026601 |
| Enterprise To Ebitda | -5.459 |
| Enterprise To Revenue | 9.842 |
| Enterprise Value | 314,694,880 |
| Eps Current Year | -1.51667 |
| Eps Forward | -1.51 |
| Eps Trailing Twelve Months | -0.86 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.3891 |
| Fifty Day Average Change | 0.33089972 |
| Fifty Day Average Change Percent | 0.061401665 |
| Fifty Two Week Change Percent | 66.01124 |
| Fifty Two Week High | 6.5 |
| Fifty Two Week High Change | -0.7800002 |
| Fifty Two Week High Change Percent | -0.120000035 |
| Fifty Two Week Low | 3.1 |
| Fifty Two Week Low Change | 2.62 |
| Fifty Two Week Low Change Percent | 0.84516126 |
| Fifty Two Week Range | 3.1 - 6.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,596,547,800,000 |
| Float Shares | 32,962,210 |
| Forward Eps | -1.51 |
| Forward P E | -3.7880793 |
| Free Cashflow | -31,812,624 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 86 |
| Fullday Change | -0.19000006 |
| Fullday Change Percent | -3.214891 |
| Fullday Price | 5.72 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.99509 |
| Gross Profits | 31,819,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.2442 |
| Held Percent Institutions | 0.47803003 |
| Implied Shares Outstanding | 60,105,049 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral vascular disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania. |
| Long Name | Orchestra BioMed Holdings, Inc. |
| Market | us_market |
| Market Cap | 343,800,864 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_570315390 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-13 |
| Net Income To Common | -59,572,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 355,881,995 |
| Number Of Analyst Opinions | 7 |
| Open | 5.87 |
| Operating Cashflow | -58,320,000 |
| Operating Margins | -254.04546 |
| Overall Risk | 9 |
| Phone | 215 862 5797 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 5.72 |
| Post Market Time | 1,791,921,699 |
| Prev Name | Health Sciences Acquisitions Corporation 2 |
| Previous Close | 5.91 |
| Price Eps Current Year | -3.7714202 |
| Price Hint | 2 |
| Price To Book | 17.819313 |
| Price To Sales Trailing12 Months | 10.751841 |
| Profit Margins | -1.84604 |
| Quick Ratio | 8.167 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.14286 |
| Region | US |
| Regular Market Change | -0.19000006 |
| Regular Market Change Percent | -3.214891 |
| Regular Market Day High | 5.87 |
| Regular Market Day Low | 5.71 |
| Regular Market Day Range | 5.71 - 5.87 |
| Regular Market Open | 5.87 |
| Regular Market Previous Close | 5.91 |
| Regular Market Price | 5.72 |
| Regular Market Time | 1,791,921,600 |
| Regular Market Volume | 204,823 |
| Return On Assets | -0.45727003 |
| Return On Equity | -3.97301 |
| Revenue Growth | -0.895 |
| Revenue Per Share | 0.537 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 60,105,049 |
| Shares Percent Shares Out | 0.0424 |
| Shares Short | 2,547,249 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 2,460,669 |
| Short Name | Orchestra BioMed Holdings, Inc. |
| Short Percent Of Float | 0.0688 |
| Short Ratio | 7.0 |
| Source Interval | 15 |
| State | PA |
| Symbol | OBIO |
| Target High Price | 20.0 |
| Target Low Price | 9.0 |
| Target Mean Price | 12.42857 |
| Target Median Price | 11.0 |
| Total Cash | 109,963,000 |
| Total Cash Per Share | 1.83 |
| Total Debt | 70,760,000 |
| Total Revenue | 31,976,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.86 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.44305 |
| Two Hundred Day Average Change | 1.2769499 |
| Two Hundred Day Average Change Percent | 0.2874039 |
| Type Disp | Equity |
| Volume | 204,823 |
| Website | https://www.orchestrabiomed.com |
| Zip | 18,938 |